Current proteomic research is limited by difficulties in scaling studies, hindering the comprehensive analysis of proteins needed to understand complex biological processes and diseases. Traditional methods lack the throughput and scale of modern genomics, impeding advancements in personalized medicine and multiomic research.

Encodia's ProteoCode™ technology addresses this limitation by reverse-translating peptide sequences into DNA libraries, enabling protein sequencing at a scale comparable to next-generation sequencing (NGS). This approach uses affinity reagent binders with DNA barcode tags to identify amino acids within peptides, creating a library of billions of elements for in-depth protein analysis. The resulting data integrates with multiomic approaches, providing researchers with comprehensive insights into cellular processes and accelerating discoveries in human health. By scaling proteomic studies, Encodia facilitates a deeper understanding of biology and enables personalized medicine approaches.

Reverse-translation of peptide sequences into DNA libraries for high-throughput protein sequencing.

Compatibility with next-generation sequencing (NGS) platforms for scalable analysis.

Affinity reagent binders with DNA barcode tags for amino acid identification.

Ability to create billions of library elements, each identifying an amino acid in the peptide.

Integration with multiomic data analysis pipelines.

The primary target audience includes researchers and scientists in the fields of proteomics, genomics, personalized medicine, and multiomics, as well as pharmaceutical and biotechnology companies.